Recombinant BCG Vaccine Expressing Multistage Antigens of Provides Long-term Immunity Against Tuberculosis in BALB/c Mice

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2024 Jan 23

PMID 38258510

Authors

Danang Fang

Ruihuan Wang

Xueting Fan

Machao Li

Chenyu Qian

Bin Cao

Jinjie Yu

Haican Liu

Yongliang Lou

Kanglin Wan

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB) caused by (Mtb) persistently kills nearly 1.5 million lives per year in the world, whereas the only licensed TB vaccine BCG exhibits unsatisfactory efficacy in adults. Taking BCG as a vehicle to express Mtb antigens is a promising way to enhance its efficacy against Mtb infection. In this study, the immune efficacy of recombination BCG (rBCG-ECD003) expressing specific antigens ESAT-6, CFP-10, and nDnaK was evaluated at different time points after immunizing BALB/c mice. The results revealed that rBCG-ECD003 induced multiple Th1 cytokine secretion including IFN-γ, TNF-α, IL-2, and IL-12 when compared to the parental BCG. Under the action of PPD or ECD003, rBCG-ECD003 immunization resulted in a significant increase in the proportion of IL-2 and IFN-γIL-2 CD4T cells. Importantly, rBCG-ECD003 induced a stronger long-term humoral immune response without compromising the safety of the parental BCG vaccine. By means of the protective efficacy assay , rBCG-ECD003 showed a greater capacity to inhibit Mtb growth in the long term. Collectively, these features of rBCG-ECD003 indicate long-term protection and the promising effect of controlling Mtb infection.

References

OGarra A, Redford P, McNab F, Bloom C, Wilkinson R, Berry M . The immune response in tuberculosis. Annu Rev Immunol. 2013; 31:475-527. DOI: 10.1146/annurev-immunol-032712-095939. View

Pym A, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A . Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med. 2003; 9(5):533-9. DOI: 10.1038/nm859. View

Li H, Wang X, Wang B, Fu L, Liu G, Lu Y . Latently and uninfected healthcare workers exposed to TB make protective antibodies against . Proc Natl Acad Sci U S A. 2017; 114(19):5023-5028. PMC: 5441709. DOI: 10.1073/pnas.1611776114. View

Sterne J, Rodrigues L, Guedes I . Does the efficacy of BCG decline with time since vaccination?. Int J Tuberc Lung Dis. 1998; 2(3):200-7. View

Havlir D, Barnes P . Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1999; 340(5):367-73. DOI: 10.1056/NEJM199902043400507. View

Winchell C, Nyquist S, Chao M, Maiello P, Myers A, Hopkins F . CD8+ lymphocytes are critical for early control of tuberculosis in macaques. J Exp Med. 2023; 220(12). PMC: 10579699. DOI: 10.1084/jem.20230707. View

Hamza T, Barnett J, Li B . Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci. 2010; 11(3):789-806. PMC: 2869233. DOI: 10.3390/ijms11030789. View

Yu J, Fan X, Luan X, Wang R, Cao B, Qian C . A novel multi-component protein vaccine ECP001 containing a protein polypeptide antigen nPstS1 riching in T-cell epitopes showed good immunogenicity and protection in mice. Front Immunol. 2023; 14:1138818. PMC: 10161251. DOI: 10.3389/fimmu.2023.1138818. View

Feng C, Jankovic D, Kullberg M, Cheever A, Scanga C, Hieny S . Maintenance of pulmonary Th1 effector function in chronic tuberculosis requires persistent IL-12 production. J Immunol. 2005; 174(7):4185-92. DOI: 10.4049/jimmunol.174.7.4185. View

10.

Fan X, Li X, Wan K, Zhao X, Deng Y, Chen Z . Construction and immunogenicity of a T cell epitope-based subunit vaccine candidate against Mycobacterium tuberculosis. Vaccine. 2021; 39(47):6860-6865. DOI: 10.1016/j.vaccine.2021.10.034. View

11.

Khader S, Bell G, Pearl J, Fountain J, Rangel-Moreno J, Cilley G . IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol. 2007; 8(4):369-77. DOI: 10.1038/ni1449. View

12.

Aagaard C, Hoang T, Dietrich J, Cardona P, Izzo A, Dolganov G . A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med. 2011; 17(2):189-94. DOI: 10.1038/nm.2285. View

13.

Trutneva K, Shleeva M, Demina G, Vostroknutova G, Kaprelyans A . One-Year Old Dormant, "Non-culturable" Preserves Significantly Diverse Protein Profile. Front Cell Infect Microbiol. 2020; 10:26. PMC: 7025520. DOI: 10.3389/fcimb.2020.00026. View

14.

Tanner R, Hoogkamer E, Bitencourt J, White A, Boot C, Sombroek C . The direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells. F1000Res. 2021; 10:257. PMC: 8097740. DOI: 10.12688/f1000research.51640.2. View

15.

Tameris M, Hatherill M, Landry B, Scriba T, Snowden M, Lockhart S . Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013; 381(9871):1021-8. PMC: 5424647. DOI: 10.1016/S0140-6736(13)60177-4. View

16.

Houben R, Dodd P . The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med. 2016; 13(10):e1002152. PMC: 5079585. DOI: 10.1371/journal.pmed.1002152. View

17.

Fay A, Glickman M . An essential nonredundant role for mycobacterial DnaK in native protein folding. PLoS Genet. 2014; 10(7):e1004516. PMC: 4109909. DOI: 10.1371/journal.pgen.1004516. View

18.

Flynn J, GOLDSTEIN M, Chan J, Triebold K, Pfeffer K, Lowenstein C . Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995; 2(6):561-72. DOI: 10.1016/1074-7613(95)90001-2. View

19.

Reed S, Coler R, Dalemans W, Dalemans W, Tan E, Dela Cruz E . Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci U S A. 2009; 106(7):2301-6. PMC: 2650151. DOI: 10.1073/pnas.0712077106. View

20.

Komine-Aizawa S, Mizuno S, Kawano A, Hayakawa S, Matsuo K, Honda M . The Induction of Antigen 85B-Specific CD8 T Cells by Recombinant BCG Protects against Mycobacterial Infection in Mice. Int J Mol Sci. 2023; 24(2). PMC: 9862620. DOI: 10.3390/ijms24020966. View